A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants
NCT02985632 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2017-02-06
Summary
An oral dose of BMS-986141 administered in Hepatic Impairment and Healthy Participants to evaluate pharmacokinetics in this patient population.
Conditions
- Hepatic Impairment
Interventions
- DRUG
-
BMS-986141
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-01-11
- Primary Completion
- 2017-05-18
- Completion
- 2017-07-07
Countries
- United States
Study Locations
More Related Trials
-
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
NCT01019070 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
NCT07248839 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage
NCT03890809 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
NCT03515980 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
NCT04249284 ·Status: COMPLETED ·Phase: PHASE1
-
Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020
NCT02068053 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants
NCT03210909 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants
NCT05981963 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
NCT05707390 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
NCT04536961 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
NCT01708889 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
NCT02957448 ·Status: COMPLETED ·Phase: PHASE1
-
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
NCT04604496 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants
NCT03362437 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
NCT00382668 ·Status: COMPLETED
-
A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function
NCT04237831 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects
NCT02880670 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects
NCT02959060 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants
NCT05567510 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
NCT04056468 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics
NCT00692341 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
NCT02387814 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants
NCT06088264 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
NCT05517525 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
NCT02857868 ·Status: COMPLETED ·Phase: PHASE1